Inovio Pharmaceuticals Earnings Estimate

INO
 Stock
  

USD 1.83  0.04  2.23%   

Many public companies, such as Inovio Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Inovio Pharmaceuticals' earnings estimates, investors can diagnose different trends across Inovio Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes.
Inovio Pharmaceuticals is projected to generate -1.26 in earnings per share on the 31st of December 2021. Inovio Pharmaceuticals earnings estimates module stress-tests analyst consensus about projected Inovio Pharmaceuticals EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Please see Risk vs Return Analysis.
  
Gross Profit is expected to rise to about 1.8 M this year, although the value of Profit Margin will most likely fall to (69.86) .

Inovio Pharmaceuticals Earnings Estimation Breakdown

Calculation of earning per share of Inovio Pharmaceuticals is based on official Zacks consensus of 4 analysts regarding Inovio Pharmaceuticals future annual earnings. Given the historical accuracy of 90.91%, the future earnings per share of Inovio Pharmaceuticals is estimated to be -1.26 with the lowest and highest values of -1.32 and -1.14, respectively. Please note that this consensus of annual earnings estimates for Inovio Pharmaceuticals is an estimate of EPS before non-recurring items and including employee stock options expenses
  Current EPS -1.54
-1.32
Lowest
Expected EPS -1.26
-1.14
Highest

Inovio Pharmaceuticals Earnings Projection Consensus

Suppose the current estimates of Inovio Pharmaceuticals' value are higher than the current market price of the Inovio Pharmaceuticals stock. In this case, investors may conclude that Inovio Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Inovio Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

4

90.91%

-1.542

-1.26

Inovio Pharmaceuticals Earnings per Share Projection vs Actual

Actual Earning per Share of Inovio Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Inovio Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Inovio Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Inovio Pharmaceuticals Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Inovio Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Inovio Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.

Inovio Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Inovio Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-11-08
2022-09-30-0.3-0.150.1550 
2022-08-09
2022-06-30-0.31-0.46-0.1548 
2022-05-10
2022-03-31-0.34-0.36-0.02
2022-03-01
2021-12-31-0.32-0.5-0.1856 
2021-11-09
2021-09-30-0.33-0.290.0412 
2021-08-09
2021-06-30-0.25-0.39-0.1456 
2021-05-10
2021-03-31-0.18-0.27-0.0950 
2021-03-01
2020-12-31-0.22-0.140.0836 
2020-11-09
2020-09-30-0.190.110.3157 
2020-08-10
2020-06-30-0.17-0.83-0.66388 
2020-05-11
2020-03-31-0.22-0.26-0.0418 
2020-03-12
2019-12-31-0.24-0.38-0.1458 
2019-11-12
2019-09-30-0.26-0.250.01
2019-08-08
2019-06-30-0.27-0.3-0.0311 
2019-05-09
2019-03-31-0.26-0.3-0.0415 
2019-03-12
2018-12-31-0.28-0.35-0.0725 
2018-11-08
2018-09-30-0.3-0.270.0310 
2018-08-07
2018-06-30-0.22-0.070.1568 
2018-05-09
2018-03-31-0.11-0.36-0.25227 
2018-03-14
2017-12-31-0.29-0.230.0620 
2017-11-08
2017-09-30-0.25-0.39-0.1456 
2017-08-08
2017-06-30-0.19-0.130.0631 
2017-05-10
2017-03-31-0.31-0.310
2017-03-15
2016-12-31-0.3-0.35-0.0516 
2016-11-09
2016-09-30-0.27-0.28-0.01
2016-08-08
2016-06-30-0.21-0.26-0.0523 
2016-05-09
2016-03-31-0.14-0.110.0321 
2016-03-14
2015-12-31-0.2-0.26-0.0630 
2015-11-09
2015-09-300.040.070.0375 
2015-08-10
2015-06-30-0.13-0.090.0430 
2015-05-11
2015-03-31-0.11-0.17-0.0654 
2015-03-16
2014-12-31-0.1-0.12-0.0220 
2014-11-10
2014-09-30-0.14-0.120.0214 
2014-08-11
2014-06-30-0.19-0.180.01
2014-05-12
2014-03-31-0.16-0.2-0.0425 
2014-03-17
2013-12-31-0.14-0.28-0.14100 
2013-11-12
2013-09-30-0.1-0.64-0.54540 
2013-08-09
2013-06-30-0.14-0.24-0.171 
2013-05-10
2013-03-31-0.17-0.24-0.0741 
2013-03-18
2012-12-31-0.18-0.01870.161389 
2012-11-07
2012-09-30-0.14-0.2-0.0642 
2012-08-09
2012-06-30-0.17-0.120.0529 
2012-05-09
2012-03-31-0.18-0.24-0.0633 
2012-03-15
2011-12-31-0.2-0.160.0420 
2011-11-07
2011-09-30-0.13-0.16-0.0323 
2011-08-08
2011-06-30-0.19-0.080.1157 
2011-05-11
2011-03-31-0.15-0.080.0746 
2011-03-17
2010-12-31-0.15-0.28-0.1386 
2010-11-15
2010-09-30-0.11-0.040.0763 
2010-08-16
2010-06-30-0.08-0.28-0.2250 
2010-05-17
2010-03-31-0.18-0.080.155 
2010-03-29
2009-12-31-0.16-0.28-0.1275 
2009-11-16
2009-09-30-0.2-0.120.0840 
2009-08-19
2009-06-30-0.24-0.76-0.52216 
2009-05-15
2009-03-31None-0.3147None
2009-03-31
2008-12-31-0.28-0.32-0.0414 
2008-11-07
2008-09-30-0.38-0.20.1847 
2008-08-07
2008-06-30-0.28-0.36-0.0828 
2008-05-09
2008-03-31-0.44-0.280.1636 
2008-03-17
2007-12-31-0.47-0.080.3982 
2007-11-08
2007-09-30-0.39-0.44-0.0512 
2007-08-08
2007-06-30-0.4-0.44-0.0410 
2007-05-09
2007-03-31-0.37-0.44-0.0718 
2007-03-16
2006-12-31-0.43-0.56-0.1330 
2006-11-08
2006-09-30-0.4-0.44-0.0410 
2006-08-08
2006-06-30-0.36-0.4-0.0411 
2006-05-09
2006-03-31-0.44-0.360.0818 
2006-03-16
2005-12-31-0.64-2.4-1.76275 
2005-11-09
2005-09-30-0.86-0.640.2225 
2005-08-09
2005-06-30-0.92-0.440.4852 
2005-05-10
2005-03-31-0.88-0.880
2005-03-15
2004-12-31-0.82-0.84-0.02
2004-11-15
2004-09-30-0.52-0.8-0.2853 
2004-08-09
2004-06-30None-0.1338None
2004-05-15
2004-03-31-0.64-0.40.2437 
2004-03-30
2003-12-31-0.48-0.480
2003-11-12
2003-09-30None-2.4594None
2003-07-16
2003-06-30None-0.4427None
2003-03-31
2003-03-31None-1.2293None

About Inovio Pharmaceuticals Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Inovio Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Inovio Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Inovio Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Inovio Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Technical Analysis Now

   

Technical Analysis

Check basic technical indicators and analysis based on most latest market data
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inovio Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for analysis

When running Inovio Pharmaceuticals price analysis, check to measure Inovio Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovio Pharmaceuticals is operating at the current time. Most of Inovio Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Inovio Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inovio Pharmaceuticals' price. Additionally, you may evaluate how the addition of Inovio Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Is Inovio Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
446.6 M
Quarterly Revenue Growth YOY
30.382
Return On Assets
(0.43) 
Return On Equity
(0.92) 
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Inovio Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.